Introduction
HIV-1 infection, viremia, virological failure
HIV-1 INFECTION, CHRONIC INFLAMMATION, VIREMIA
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a guideline-recommended regimen for the treatment of HIV-1 infection in both naïve and experienced patients that demonstrated high efficacy and barrier to resistance without occurrence of incident resistance among individuals experiencing virological failure (Despite the lack of evidence for a difference in rates of virological suppression, whether levels of chronic inflammation differ after effective treatment with 2DR Concerning viral replication, DTG/3TC in either naïve or experienced patients was shown to be non-inferior to 3DRs for the outcomes of target not detectable viremia or viral blips (Concerning chronic inflammation, the TANGO randomized trial, comparing PLWH switching to DTG/3TC to those remaining on a 3DR, has shown a statistically significant 16% increase in interleukin (IL)-6 plasma levels at 48 weeks in the first group (The aim of this randomized clinical trial was to compare the immunophenotype and inflammatory biomarkers in PLWH with viral load ≤50 copies/mL switching from a 3DR to B/F/TAF 